GlaxoSmithKline plc (LON:GSK) had its price objective reduced by equities research analysts at Berenberg Bank from GBX 1,835 ($24.21) to GBX 1,760 ($23.23) in a research note issued on Thursday. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s target price indicates a potential upside of 29.32% from the company’s current price.
Several other research analysts have also commented on GSK. Citigroup Inc. lowered GlaxoSmithKline plc from a “buy” rating to a “neutral” rating and set a GBX 1,700 ($22.43) price target for the company. in a research report on Wednesday, July 5th. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 1,900 ($25.07) price target on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. J P Morgan Chase & Co reiterated a “neutral” rating and issued a GBX 1,750 ($23.09) price target on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Friday, July 14th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a GBX 1,700 ($22.43) price target on shares of GlaxoSmithKline plc in a research report on Tuesday, July 18th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have issued a buy rating to the company. GlaxoSmithKline plc has a consensus rating of “Hold” and a consensus target price of GBX 1,619.75 ($21.37).
GlaxoSmithKline plc (LON:GSK) traded up GBX 9.50 ($0.13) on Thursday, reaching GBX 1,361 ($17.96). The company had a trading volume of 7,047,222 shares.
GlaxoSmithKline plc (LON:GSK) last released its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%.
In other GlaxoSmithKline plc news, insider Simon Dingemans acquired 1,076 shares of GlaxoSmithKline plc stock in a transaction that occurred on Thursday, October 12th. The stock was bought at an average price of GBX 1,527 ($20.15) per share, with a total value of £16,430.52 ($21,681.87). Also, insider Urs Rohner acquired 473 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, October 25th. The stock was acquired at an average cost of GBX 1,518 ($20.03) per share, with a total value of £7,180.14 ($9,474.98). Insiders purchased 1,574 shares of company stock valued at $2,398,888 in the last three months.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.